Please assess the completion status of the following clinical trial:

Trial Title: The Use of Finasteride to Reduce Hematuria and Hematospermia Following TRUS Prostate Biopsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent prior to the participation in any study related activity.~2. Male subject already identified as requiring TRUS prostate biopsy for unrelated medical reasons.~Exclusion Criteria:~1. Suspected or known liver disease.~2. Suspected or known hematological disorders.~3. Subjects who are candidates for immediate surgery.~4. Known hypersensitivity to any component of the product.

- Gender: MALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): 5mg finasteride orally, daily for 2 weeks prior to prostate biopsy and one week following prostate biopsy.

Based on this trial design, predict the completion outcome and termination type (if applicable).